United Kingdom (UK)
Recombinant monoclonal antibody to Cisplatin modified DNA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma CP9/19.
Alternative Name(s) of Target: ICR4
Immunogen: The original antibody was generated by immunizing F344 rats with cisplatin-modified native DNA.
Specificity: Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.
Application Notes: This antibody binds to cisplatin-modified DNA and enables the quantification of cisplatin-induced adducts on DNA (Tilby et al., 1991; PMID: 1703029). This antibody has also been used for the isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines (McGurk et al., 2001; PMID: 11494859). This antibody has been used for IHC on mouse samples (Rainey et al., 2016; PMID: 27122034). This antibody was used in an IF assay to detect platinum-DNA adducts (Nicholson et al., 2022; PMID: 35778553).
Antibody first published in:
Tilby et al. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res. 1991 Jan 1;51(1):123-9 PMID:1703029
Note on publication:
The original publication describes the development and characterization of a monoclonal antibody-based assay (ICR4) enabling the sensitive quantitation of cisplatin-induced DNA adducts, down to levels relevant for inducing toxic effects in cells in vitro and in vivo.
